RR-11a

• Description :

  RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM) . RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) [1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Legumain

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/RR-11a.html

• Concentration :

  10mM

• Purity :

  98.08

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2

• Molecular Formula :

  C24H28N6O10

• Molecular Weight :

  560.51

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7 (6) :665-73.|[2]Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C|[3]Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11 (11) :1014. Published 2020 Nov 26.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1361390-56-8]